Tjiam M Christian, Morshidi Mazmah A, Sariputra Lucy, Martin Jeffrey N, Deeks Steven G, Tan Dino B A, Lee Silvia, Fernandez Sonia, French Martyn A
*School of Biomedical Sciences, University of Western Australia, Perth, Western Australia, Australia †Division of Clinical Epidemiology, University of California, San Francisco, CA ‡School of Medicine, University of California, San Francisco, CA §Stem Cell Unit, Institute of Respiratory Health, Perth, Western Australia, Australia ‖Department of Microbiology and Infectious Diseases, Royal Perth Hospital and PathWest Laboratory Medicine, Perth, Western Australia, Australia ¶School of Biomedical Sciences, Curtin University, Perth, Western Australia, Australia #Medical School, University of Western Australia, Perth, Western Australia, Australia **Department of Clinical Immunology, Royal Perth Hospital and PathWest Laboratory Medicine, Perth, Western Australia, Australia.
J Acquir Immune Defic Syndr. 2017 Nov 1;76(3):e90-e92. doi: 10.1097/QAI.0000000000001477.
To expand upon our previous observation that HIV-1 Gag-specific IgG antibodies were highest in HIV controllers not carrying HLA-B57:01, we analysed these antibodies in a larger cohort of viremic controllers (VCs) or elite controllers (ECs) considering carriage of ‘protective’ HLA-B alleles. HIV-1 p24-specific IgG1 and IgG2 antibodies were higher only in HLA-B57:01 VCs but there were no differences in ECs. Associations of HIV-1 gp140-specific IgG antibodies with HLA-B*57:01 carriage were inconsistent amongst VCs and ECs.
为进一步阐述我们之前的观察结果，即不携带HLA - B57:01的HIV控制者中HIV - 1 Gag特异性IgG抗体水平最高，我们在更大的病毒血症控制者（VCs）或精英控制者（ECs）队列中分析了这些抗体，并考虑了“保护性”HLA - B等位基因的携带情况。仅在携带HLA - B57:01的VCs中，HIV - 1 p24特异性IgG1和IgG2抗体水平较高，但在ECs中无差异。在VCs和ECs中，HIV - 1 gp140特异性IgG抗体与HLA - B*57:01携带之间的关联并不一致。
